Shu-Fen Chiang
5PUBLICATIONS
11CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 29, 2024
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy.Kevin Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke
|Oct 31, 2022
A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors.Kevin Chih-Yang Huang, Chia-Ying Lai, Wei-Ze Hung
|May 24, 2021
An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1).Shu-Fen Chiang, Kevin Chih-Yang Huang, William Tzu-Liang Chen
|Mar 13, 2021
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.Shu-Fen Chiang, Kevin Chih-Yang Huang, William Tzu-Liang Chen
|Dec 19, 2020
Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.Kevin Chih-Yang Huang, Shu-Fen Chiang, Tsung-Wei Chen
Pageof 1
Frequent Collaborators
5 joint publications
Kevin Chih-Yang Huang
5 joint publications
K S Clifford Chao
1 joint publications
Chia-Ying Lai
1 joint publications
Wei-Ze Hung
1 joint publications
Hsin-Yu Chang
1 joint publications
Pei-Chun Lin
1 joint publications
Tao-Wei Ke
1 joint publications
Ji-An Liang
1 joint publications
An-Cheng Shiau
1 joint publications
Pei-Chen Yang
